BSE filing, NSE: FISCHER. Summary written from the filing by ALFA Finder's alert engine.
Fischer Medical Ventures Ltd: key numbers
- Share price
- ₹24.66
- Market cap
- ₹1,708 Cr
- Revenue (annual)
- ₹308.6 Cr
- Net profit (annual)
- ₹31.02 Cr
- P/E (TTM)
- 57.3×Sector 34.1×
- Promoter holding
- 63.08%+0.93% QoQ
- FII holding
- 6.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fischer Medical Ventures Ltd
All →Fischer Medical Ventures Management Change
Fischer Medical Ventures appointed Mr. Chan Sing En as Independent Director of SG subsidiary FMV Global Innovations, effective 27 Oct 2026. No financial consideration involved.
Fischer Medical Ventures Other Announcement
Fischer Medical Ventures Ltd filed its quarterly shareholding pattern under Regulation 31. This routine disclosure presents the company's current ownership structure.
Fischer Medical Ventures Annual General Meeting
Fischer Medical Ventures Ltd has issued a Postal Ballot Notice seeking shareholder approval for creating security on subsidiary assets and promoter share pledges for proposed NCD issuance.
Fischer Medical Ventures Board Meeting Outcome
Fischer Medical Ventures' board approved a postal ballot notice for RPT consent and borrowing limits, and appointed a scrutinizer. No material transaction or financial figure was decided at this meeting.
Fischer Medical Ventures Annual General Meeting
Fischer Medical Ventures Limited conducted its 33rd Annual General Meeting via video conferencing on September 29, 2026, with the requisite quorum present.
Fischer Medical Ventures Other Announcement
Fischer Medical Ventures' subsidiaries declared dividends totaling ₹26.95 Crore. This update provides financial information regarding subsidiary cash flows to the exchange.
- Value
- ₹26.95 Cr
Other regulatory approval announcements
All →City Union Bank Regulatory Approval
City Union Bank disclosed RBI approval for appointing Shri Sankaran G as Executive Director (Whole-time Director) for three years. The board appointment and formal disclosures will follow later.
- Execution
- Three years from the date of taking charge
Lupin Regulatory Approval
Lupin received US FDA approval for its generic Amifampridine Tablets 10 mg ANDA. As a first-to-file applicant, it is eligible for 180-day shared generic exclusivity.
Som Distilleries & Breweries Regulatory Approval
Som Distilleries received manufacturing licences for its Bhopal plant from the Madhya Pradesh Excise Department, plus product label and rate approvals. Manufacturing and sales are expected to resume soon.
AGI Infra Regulatory Approval
Agi Infra received RERA registration PBRERA-SAS80-PR1452-102026 from Punjab RERA for its Utopia by AGI group housing project in New Chandigarh. The registration is valid until 30 March 2031.
- Execution
- Valid up to March 30, 2031
360 One Wam Regulatory Approval
360 ONE Distribution Services' IFSC branch, a subsidiary of 360 ONE WAM, received an IFSCA Certificate of Registration to act as broker dealer, clearing member, depository participant, research entity and distributor. This is a regulatory licence authorising new activities in the IFSC.
Nesco Regulatory Approval
Nesco Limited received a Commencement Certificate from BMC for Tower-2 and Hall-1 at Nesco Center, Goregaon. The company can now proceed with construction and development of the proposed projects, valid until 29 October 2027.